Skip to main content

Pay for performance and comorbidity

While the use of pay for performance as a quality improvement tool in health care is increasing, little is known about the impact of these programs on the quality of care delivered to patients with multiple conditions. Pay for performance schemes, such as the Quality and Outcomes Framework in the UK, could impact the quality of care delivered to patients with complex medical problems in several ways. A study published by myself and colleagues in the Journal of the Royal Society of Medicine suggested that introduction of pay-for-performance in primary care in the UK has not had a negative impact on the quality of care delivered to patients with multiple medical conditions. Rather, patients with co-morbid medical conditions seem to have benefited more than those without co-morbidity. This is reassuring given that previous studies have found that patients with multiple medical conditions are more likely to be excluded from performance reporting in pay for performance programs. Our findings provide no support for setting lower treatment targets for patients with multiple conditions within quality improvement programs and pay-for-performance schemes. This is important given that the longer-term benefits of good diabetes control are now firmly established and that associated health gain may be greatest in high-risk groups with existing co-morbid conditions such as coronary heart disease and hypertension.

Comments

Popular posts from this blog

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...